buoyantintelligence
  • 01Overview
  • 02Portfolio
  • 03Company Atlas
    • Buoyant book
    • All listed companies
  • 04Screener & valuation
  • 05House view
  • 06Markets
  • 07India top-down
  • 08Investors
  • 09Library & data
Release
August 2026 · rev 1
Opportunities PMS · Published
As at 31 Aug 2026 · IST₹ · ₹ cr · BSE 500 TRI
Present
Internal working platform. Published figures are extracted from the August 2026 source package and reviewed; reference prices and fundamentals are unlicensed working data, not for redistribution. Past performance is not indicative of future returns.
All listed companies/Jubilant Pharmova Limited
03 /Listed universe · Healthcare · CDMO

Jubilant Pharmova Limited.

Value itCompareScreener.in ↗Tijori ↗NSE ↗BSE ↗
Snapshot

Healthcare · CDMO

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of pulmonary embolism, cancer, coronary artery disease, and other diseases. Its Allergy Immunotherapy segment provides specialized diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacture, distribution, sale, and marketing of generic formulations for therapeutic areas, such as cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment provides drug discovery services and active pharmaceutical ingredients. Its Proprietary Novel Drugs segment offers patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organizations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida, India.

Market cap
₹17,055 cr
P/E (TTM)
48.8
P/B (latest)
2.4
ROE (TTM)
5.6%
ROCE (TTM)
7%
Sales CAGR 3y
9.6%
PAT CAGR 3y
0%
Debt / equity
0.45x
Promoter
47.7%
Dividend yield
0.47%
Size
Small
Codes
JUBLPHARMA · 530019
Price

₹1,060.45 · 28 Sept 2026

1M
+20.1%
3M
+10.0%
6M
+25.6%
YTD
+0.2%
1Y
+1.7%
3Y
+149.1%
5Y
—
vs 52w high
−10.2%

52-week ₹807.65 – ₹1,181.2 · ADTV ₹24.7 cr · price-only.

Trend

Sales and net profit by fiscal year, ₹ crore

Not in the Buoyant book: no house thesis or target is carried. Exchange masters, Tijori and the reference price feed as stated on each tab. All listed companies · NSE EQ